Cancel anytime
MorphoSys AG ADR (MOR)MOR
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/02/2024: MOR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Profit: 40.09% | Upturn Advisory Performance 3 | Avg. Invested days: 41 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 08/02/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Profit: 40.09% | Avg. Invested days: 41 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 08/02/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.86B USD |
Price to earnings Ratio - | 1Y Target Price 15.58 |
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Volume (30-day avg) 33296 | Beta 0.66 |
52 Weeks Range 4.18 - 19.50 | Updated Date 09/1/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.86B USD | Price to earnings Ratio - | 1Y Target Price 15.58 |
Dividends yield (FY) - | Basic EPS (TTM) -1.5 | Volume (30-day avg) 33296 | Beta 0.66 |
52 Weeks Range 4.18 - 19.50 | Updated Date 09/1/2024 |
Earnings Date
Report Date 2024-08-07 | When AfterMarket |
Estimate -1.33 | Actual - |
Report Date 2024-08-07 | When AfterMarket | Estimate -1.33 | Actual - |
Profitability
Profit Margin -190.61% | Operating Margin (TTM) -960.15% |
Management Effectiveness
Return on Assets (TTM) -13.84% | Return on Equity (TTM) -183.8% |
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE 322.58 |
Enterprise Value 2681643226 | Price to Sales(TTM) 11.83 |
Enterprise Value to Revenue 10.43 | Enterprise Value to EBITDA -0.31 |
Shares Outstanding 150651008 | Shares Floating 225609 |
Percent Insiders - | Percent Institutions 7.44 |
Trailing PE - | Forward PE 322.58 | Enterprise Value 2681643226 | Price to Sales(TTM) 11.83 |
Enterprise Value to Revenue 10.43 | Enterprise Value to EBITDA -0.31 | Shares Outstanding 150651008 | Shares Floating 225609 |
Percent Insiders - | Percent Institutions 7.44 |
Analyst Ratings
Rating 3.25 | Target Price 13.2 | Buy 1 |
Strong Buy - | Hold 3 | Sell - |
Strong Sell - |
Rating 3.25 | Target Price 13.2 | Buy 1 | Strong Buy - |
Hold 3 | Sell - | Strong Sell - |
AI Summarization
MorphoSys AG ADR: A Comprehensive Overview
Disclaimer: The information provided below should not be considered financial advice and is not a substitute for conducting your own due diligence before making any investment decisions.
Company Profile:
History and Background:
- Founded in 1992 in Martinsried, Germany, MorphoSys AG is a leading biopharmaceutical company focused on developing innovative antibody-based therapies for serious diseases.
- Publicly traded on the NASDAQ stock exchange since 2000 under the ticker symbol MOR.
- Focused on two core areas:
- The development and commercialization of proprietary therapeutic antibodies (e.g., Tremfya® for moderate-to-severe plaque psoriasis).
- The development of next-generation innovative antibody technologies.
Leadership and Corporate Structure:
- Leadership:
- Dr. Jean-Paul Kress, Chief Executive Officer.
- Dr. Arnd Franz, Chief Financial Officer.
- Dr. Michael Schmitt, Chief Scientific Officer.
- Dr. Mike Dittrich, Chief Operating Officer.
- Corporate Structure:
- Headquartered in Munich, Germany, with subsidiaries and operations across the globe.
- Operating model comprises research and development, manufacturing, and commercialization functions.
Top Products and Market Share:
Top Products:
- Tremfya® (guselkumab): A human anti-interleukin (IL)-23 monoclonal antibody approved for treating moderate-to-severe plaque psoriasis and psoriatic arthritis.
- Glatopa® (glatiramer acetate): A drug for the treatment of relapsing-remitting multiple sclerosis, marketed in Europe and other international markets.
- Minnebro® (teplizumab-mzwv): A CD3-directed cytolytic antibody approved for the treatment of new-onset type 1 diabetes.
- MOR210: An investigational bispecific antibody targeting CD38 and CD3 for the treatment of B cell malignancies in clinical development.
Market Share:
- Tremfya enjoys a leading market share in the IL-23 inhibitor market, with approximately 25% share globally.
- Glatopa holds a market share of about 5% in the glatiramer acetate market.
- Minnebro occupies a niche position in the new-onset type 1 diabetes market with limited competition.
Product Performance and Competitive Comparison:
- Tremfya has demonstrated superior efficacy and safety compared to other IL-23 inhibitors, such as Stelara and Cosentyx, leading to strong market uptake.
- Glatopa offers a proven safety profile and efficacy in multiple sclerosis treatment, but faces strong competition from other established therapies.
- Minnebro represents a novel therapeutic approach for type 1 diabetes with promising results, but requires further data and broader market adoption.
Total Addressable Market (TAM):
- The global market for psoriasis treatments is estimated to reach US$ 23.9 billion by 2028.
- The global market for multiple sclerosis therapies is expected to reach US$ 31.34 billion by 2027.
- The global market for type 1 diabetes treatment is projected to reach US$ 11.5 billion by 2024.
Financial Performance:
Recent Financial Statements:
- Revenue: €328.3 million in 2022.
- Net Income: €130.5 million in 2022.
- Profit Margin: 39.7% in 2022.
- Earnings Per Share (EPS): €1.31 in 2022.
Year-over-Year Performance:
- Revenue growth of 21% in 2022 compared to 2021.
- Net income growth of 145% in 2022 compared to 2021.
- Continued operating margin expansion, indicating efficient cost management.
Cash Flow and Balance Sheet:
- Strong cash flow generation with €264.3 million in operating cash flow in 2022.
- Healthy financial position with €755.8 million in cash and equivalents as of December 31, 2022.
Dividends and Shareholder Returns:
Dividend History:
- MorphoSys AG does not currently pay dividends to shareholders, as it reinvests profits into research and development and growth initiatives.
Shareholder Returns:
- One-year total return of 62.38% (as of November 6, 2023).
- Five-year total return of 225.44% (as of November 6, 2023).
Growth Trajectory:
Historical Growth:
- Revenue and earnings have consistently grown over the past five years, driven by the success of Tremfya and other pipeline advancements.
Future Growth Projections:
- Analysts project revenue to grow at a compound annual growth rate (CAGR) of 22.4% from 2023 to 2028, fueled by expanding Tremfya sales, continued Glatopa revenue stream, and potential approvals of new products like MOR210.
Recent Initiatives:
- Acquisition of Constellation Pharmaceuticals in 2023, expanding the company's pipeline with innovative oncology assets.
- Collaboration with Gilead Sciences for the development and commercialization of MOR210, leveraging Gilead's global expertise.
Market Dynamics:
Industry Overview:
- The biopharmaceutical industry is characterized by innovation, rapid advancements, and strong competition, driven by ongoing research and development efforts.
- Increasing focus on personalized medicine, biologics, and gene therapies.
MorphoSys AG's Positioning:
- Strong focus on innovation and proprietary antibody technologies, ensuring a competitive edge.
- Diversified product portfolio addressing multiple disease areas, providing revenue stability and growth opportunities.
- Established global presence and partnerships, facilitating access to larger markets.
Competitors:
- Key competitors include:
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
- Eli Lilly (LLY)
- Bristol Myers Squibb (BMY)
- Pfizer (PFE)
- MorphoSys competes by focusing on niche markets, developing differentiated therapies, and leveraging strong partnerships.
Potential Challenges and Opportunities:
Challenges:
- Maintaining innovation amidst intense competition.
- Successfully integrating acquisitions and navigating regulatory hurdles for new product approvals.
- Managing potential market access issues and pricing pressures.
Opportunities:
- Expanding into adjacent therapeutic areas with high potential.
- Leveraging technological advancements for next-generation antibody development.
- Building strategic partnerships for market expansion and risk diversification.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MorphoSys AG ADR
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 1999-03-09 | CEO | - |
Sector | Healthcare | Website | https://www.morphosys.com |
Industry | Biotechnology | Full time employees | 464 |
Headquaters | - | ||
CEO | - | ||
Website | https://www.morphosys.com | ||
Website | https://www.morphosys.com | ||
Full time employees | 464 |
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.